Clinical trials
Duodenal Ulcer trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
72 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2003 | 4 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 7 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 5 |
| 2011 | 8 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 56 |
| Unknown status | 8 |
| Terminated | 4 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Takeda | 18 |
| AstraZeneca | 15 |
| Boryung Pharmaceutical Co., Ltd | 3 |
| Eisai Co., Ltd. | 3 |
| Hamamatsu University | 3 |
| Livzon Pharmaceutical Group Inc. | 3 |
| National Taiwan University Hospital | 2 |
| The Catholic University of Korea | 2 |
| Valenta Pharm JSC | 2 |
| Altinbas University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Duodenal Ulcer | 72 |
| Stomach Ulcer | 43 |
| Peptic Ulcer | 7 |
| Esophagitis, Peptic | 6 |
| Gastritis | 6 |
| Gastroesophageal Reflux | 5 |
| Gastrointestinal Hemorrhage | 4 |
| Stomach Neoplasms | 4 |
| Dyspepsia | 3 |
| Osteoarthritis | 3 |
Trials
Showing 51 to 72 of 72. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.